Cargando…

Long-term prognostic value of longitudinal measurements of blood neurofilament levels

OBJECTIVE: To assess the long-term prognostic value of an integral of longitudinal measurements of plasma neurofilament light chain levels (NfL(long)) over 12 and 24 months vs single neurofilament light chain (NfL) measurements in patients with relapsing-remitting MS (RRMS) and its additional value...

Descripción completa

Detalles Bibliográficos
Autores principales:	Häring, Dieter A., Kropshofer, Harald, Kappos, Ludwig, Cohen, Jeffrey A., Shah, Anuja, Meinert, Rolf, Leppert, David, Tomic, Davorka, Kuhle, Jens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428358/ https://www.ncbi.nlm.nih.gov/pubmed/32817406 http://dx.doi.org/10.1212/NXI.0000000000000856

Ejemplares similares

Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials
por: Leppert, David, et al.
Publicado: (2022)

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
por: Kuhle, Jens, et al.
Publicado: (2019)

Blood neurofilament light as a potential endpoint in Phase 2 studies in MS
por: Sormani, Maria Pia, et al.
Publicado: (2019)

Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis
por: Chitnis, Tanuja, et al.
Publicado: (2018)

Serum neurofilament light chain levels associations with gray matter pathology: a 5‐year longitudinal study
por: Jakimovski, Dejan, et al.
Publicado: (2019)

Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis
por: Reinert, Marie-Christine, et al.
Publicado: (2020)

Serum neurofilament light chain and optical coherence tomography measures in MS: A longitudinal study
por: Tavazzi, Eleonora, et al.
Publicado: (2020)

Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Blood neurofilament light chain at the doorstep of clinical application
por: Leppert, David, et al.
Publicado: (2019)

Serum neurofilament light chain as outcome marker for intensive care unit patients
por: Fisse, Anna Lena, et al.
Publicado: (2020)

Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis
por: Manouchehrinia, Ali, et al.
Publicado: (2020)

Longitudinal analyses of serum neurofilament light and associations with obesity indices and bioelectrical impedance parameters
por: Hermesdorf, Marco, et al.
Publicado: (2022)

Blood neurofilament light levels segregate treatment effects in multiple sclerosis
por: Delcoigne, Bénédicte, et al.
Publicado: (2020)

Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases
por: Gaiottino, Johanna, et al.
Publicado: (2013)

White matter lesion location correlates with disability in relapsing multiple sclerosis
por: Gaetano, Laura, et al.
Publicado: (2020)

Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing‐remitting multiple sclerosis
por: Langdon, Dawn W., et al.
Publicado: (2021)

Monitoring of radiologic disease activity by serum neurofilaments in MS
por: Uher, Tomas, et al.
Publicado: (2020)

Serum neurofilament light chains in MS: Association with the Timed Up and Go
por: Allali, Gilles, et al.
Publicado: (2020)

Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis
por: Disanto, Giulio, et al.
Publicado: (2017)

Association of serum neurofilament light with microglial activation in multiple sclerosis
por: Saraste, Maija, et al.
Publicado: (2023)

Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial
por: Bar-Or, Amit, et al.
Publicado: (2022)

Serum neurofilament light and tau as prognostic markers for all-cause mortality in the elderly general population—an analysis from the MEMO study
por: Rübsamen, Nicole, et al.
Publicado: (2021)

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015)

Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19
por: Ameres, Markus, et al.
Publicado: (2020)

Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2021)

Neurofilament light levels are associated with long-term outcomes in multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2019)

Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS
por: Kuhle, Jens, et al.
Publicado: (2021)

Evaluation of neurofilament light chain in the cerebrospinal fluid and blood as a biomarker for neuronal damage in experimental pneumococcal meningitis
por: Le, Ngoc Dung, et al.
Publicado: (2020)

Development of an age‐adjusted model for blood neurofilament light chain
por: Harp, Christopher, et al.
Publicado: (2022)

High serum neurofilament associates with diffuse white matter damage in MS
por: Saraste, Maija, et al.
Publicado: (2020)

Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis
por: Maggi, Pietro, et al.
Publicado: (2021)

A Method to Combine Neurofilament Light Measurements From Blood Serum and Plasma in Clinical and Population-Based Studies
por: Rübsamen, Nicole, et al.
Publicado: (2022)

Factors influencing serum neurofilament light chain levels in normal aging
por: Koini, Marisa, et al.
Publicado: (2021)

Evidence of polygenic regulation of the physiological presence of neurofilament light chain in human serum
por: Herrera-Rivero, Marisol, et al.
Publicado: (2023)

Ratio and index of Neurofilament light chain indicate its origin in Guillain‐Barré Syndrome
por: Körtvelyessy, Peter, et al.
Publicado: (2020)

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

Serum neurofilament light levels in normal aging and their association with morphologic brain changes
por: Khalil, Michael, et al.
Publicado: (2020)

Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial
por: Kuhle, Jens, et al.
Publicado: (2023)

A Longitudinal Investigation of Blood Neurofilament Light Chain Levels in Chronic Cocaine Users
por: Bavato, Francesco, et al.
Publicado: (2023)

Early life serum neurofilament dynamics predict neurodevelopmental outcome of preterm infants
por: Goeral, Katharina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rvkl0to3d68uon09f1o7qo6vvg